Lung
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Comparing Standard 75mg/m² and Fixed 50mg Cisplatin Doses in NSCLC Treatment Response and Toxicity
FEATURING
Maher Salamoon
- 36 views
- December 3, 2024
- 1
ecancer
ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr
- 266 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Discussing Key Studies on the Use of Zipalertinib, Zidesamtinib, and PM8002/BNT327 With CT in NSCLC
FEATURING
Joop Langen
- 78 views
- October 7, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients With Bone Metastases
FEATURING
Robbe Van den Begin
- 489 views
- September 26, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience
FEATURING
Kelsey Natsuhara
- 909 views
- October 14, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Completely Resected NSCLC
FEATURING
Glenwood Goss
- 19 views
- October 21, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: LBA51 DUART Trial - ctDNA Dynamics and Treatment Responses in CT-Ineligible Stage III NSCLC
FEATURING
Andrea Filippi
- 11 views
- October 11, 2024
ecancer
ESMO 2024 Insights: PIONeeR Trial - IO Resistance Pathways Investigated to Tailor Combination Advanced NSCLC Therapy
FEATURING
Pascale Tomasini
- 28 views
- October 11, 2024
ecancer
ESMO 2024 Insights: Canadian Cancer Trials Group BR.31 Study - Adjuvant Durvalumab After Complete Tumor Resection & Optional Chemo in Early Stage (IB-IIIA) NSCLC
FEATURING
Glenwood Goss
- 24 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EP0031 - Next-Generation RET Inhibitor Correlating Molecular and Clinical Responses in RET-Altered Solid Tumors
FEATURING
Elena Garralda
- 42 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced ROS1 Fusion-Positive NSCLC and Other Solid Tumors
FEATURING
Benjamin Besse
- 38 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Acquired Resistance to 1L Amivantamab + Lazertinib vs. Osimertinib in EGFR-Mutant aNSCLC - Early MARIPOSA Study Analysis
FEATURING
Benjamin Besse
- 165 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: IBI354 - Anti-HER2 ADC in Advanced Solid Tumors and Breast Cancer
FEATURING
Christina Teng
- 76 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RELATIVITY-104 Study - Nivo + Relatlimab With Platinum-Doublet Chemo vs. Nivo + Platinum-Doublet Chemo as 1L Treatment for Stage IV or Recurrent NSCLC
FEATURING
Nicolas Girard
- 139 views
- September 18, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Emerging Molecular Targets in Thymic Epithelial Tumors
FEATURING
Anja Roden
- 46 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents in Lung Cancer
FEATURING
Pilar Garrido
- 156 views
- September 26, 2024
- 1